Literature DB >> 25294900

Team work matters: dual inhibition puts non-hodgkin lymphoma under siege.

Giada Bianchi1, Irene M Ghobrial2.   

Abstract

Inhibitors of PI3K/mTOR and histone deacetylases (HDAC) are effective in non-Hodgkin lymphoma (NHL). However, clinical resistance eventually ensues and combinatory therapies are sought to prevent it. Preclinical evaluation of dual PI3K/mTOR and HDAC inhibition is synergistic against NHL, paving the way for bench-to-bedside translation. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25294900      PMCID： PMC4433012          DOI： 10.1158/1078-0432.CCR-14-2055

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

Review 1.  Anticancer activities of histone deacetylase inhibitors.

Authors:  Jessica E Bolden; Melissa J Peart; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 2.  Progress of HDAC inhibitor panobinostat in the treatment of cancer.

Authors:  Xiaoyang Li; Jian Zhang; Yuanchao Xie; Yuqi Jiang; Zhang Yingjie; Wenfang Xu
Journal:  Curr Drug Targets       Date:  2014-06       Impact factor: 3.465

3.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors:  Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

Review 4.  Double-hit B-cell lymphomas.

Authors:  Sietse M Aukema; Reiner Siebert; Ed Schuuring; Gustaaf W van Imhoff; Hanneke C Kluin-Nelemans; Evert-Jan Boerma; Philip M Kluin
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

5.  The clonal evolution of tumor cell populations.

Authors:  P C Nowell
Journal:  Science       Date:  1976-10-01       Impact factor: 47.728

6.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Authors:  Elise A Olsen; Youn H Kim; Timothy M Kuzel; Theresa R Pacheco; Francine M Foss; Sareeta Parker; Stanley R Frankel; Cong Chen; Justin L Ricker; Jean Marie Arduino; Madeleine Duvic
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

7.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Wing C Chan; Joseph M Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend B Smeland; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan L Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

Review 8.  Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.

Authors:  James S Blachly; Robert A Baiocchi
Journal:  Br J Haematol       Date:  2014-08-06       Impact factor: 6.998

9.  PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.

Authors:  Mohamed Rahmani; Mandy Mayo Aust; Elisa C Benson; LaShanale Wallace; Jonathan Friedberg; Steven Grant
Journal:  Clin Cancer Res       Date:  2014-07-28       Impact factor: 12.531

10.  PI3K signalling: the path to discovery and understanding.

Authors:  Bart Vanhaesebroeck; Len Stephens; Phillip Hawkins
Journal:  Nat Rev Mol Cell Biol       Date:  2012-02-23       Impact factor: 94.444
  10 in total
  1 in total

1.  HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells.

Authors:  Eva Juengel; Ramin Najafi; Jochen Rutz; Sebastian Maxeiner; Jasmina Makarevic; Frederik Roos; Igor Tsaur; Axel Haferkamp; Roman A Blaheta
Journal:  Oncotarget       Date:  2017-11-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.